These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 38880868)
1. Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice. Yang H; Xie Y; Li S; Bao C; Wang J; Li C; Nie J; Quan Y Hum Vaccin Immunother; 2024 Dec; 20(1):2364519. PubMed ID: 38880868 [TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study. Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261 [TBL] [Abstract][Full Text] [Related]
3. Adjuvants to the S1-subunit of the SARS-CoV-2 spike protein vaccine improve antibody and T cell responses and surrogate neutralization in mice. Becker W; Rebbani K; Duan Z; Valkov E; Bryant S; Ho M; Berzofsky JA; Olkhanud PB Sci Rep; 2024 Nov; 14(1):29609. PubMed ID: 39609527 [TBL] [Abstract][Full Text] [Related]
4. Comparison of a SARS-CoV-2 mRNA booster immunization containing additional antigens to a spike-based mRNA vaccine against Omicron BA.5 infection in hACE2 mice. Hurst JR; Naghibosadat M; Budowski P; Liu J; Samaan P; Budiman F; Kurtesi A; Qi F; Menon H; Krishnan R; Abioye J; Gingras AC; Ostrowski M; Orozco NM; Kozak RA PLoS One; 2024; 19(12):e0314061. PubMed ID: 39625929 [TBL] [Abstract][Full Text] [Related]
5. Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice. Zhu J; Wang Z; Li Y; Zhang Z; Ren S; Wang J; Xie S; Liao Z; Song B; Wu W; Yan F; Peng C J Virol; 2024 Jul; 98(7):e0052124. PubMed ID: 38874361 [TBL] [Abstract][Full Text] [Related]
6. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines. Liang CY; Raju S; Liu Z; Li Y; Asthagiri Arunkumar G; Case JB; Scheaffer SM; Zost SJ; Acreman CM; Gagne M; Andrew SF; Carvalho Dos Anjos DC; Foulds KE; McLellan JS; Crowe JE; Douek DC; Whelan SPJ; Elbashir SM; Edwards DK; Diamond MS Nature; 2024 Jun; 630(8018):950-960. PubMed ID: 38749479 [TBL] [Abstract][Full Text] [Related]
8. A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity. Klinkardt U; Schunk M; Ervin J; Schindler C; Sugimoto D; Rankin B; Amann R; Monti M; Kutschenko A; Schumacher C; Huber K; Zeder A; Heikkila N; Didierlaurent AM; Schwarz SE; Derouazi M Hum Vaccin Immunother; 2024 Dec; 20(1):2410574. PubMed ID: 39397784 [TBL] [Abstract][Full Text] [Related]
9. Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine. Petrovsky N Hum Vaccin Immunother; 2024 Dec; 20(1):2363016. PubMed ID: 38839044 [TBL] [Abstract][Full Text] [Related]
10. One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization. Gu M; Torres JL; Li Y; Van Ry A; Greenhouse J; Wallace S; Chiang CI; Pessaint L; Jackson AM; Porto M; Kar S; Li Y; Ward AB; Wang Y Emerg Microbes Infect; 2021 Dec; 10(1):2016-2029. PubMed ID: 34651563 [No Abstract] [Full Text] [Related]
11. A Dual-Adjuvanted Parenteral-Intranasal Subunit Nanovaccine generates Robust Systemic and Mucosal Immunity Against SARS-CoV-2 in Mice. Pandey B; Wang Z; Jimenez A; Bhatia E; Jain R; Beach A; Maniar D; Hosten J; O'Farrell L; Vantucci C; Hur D; Noel R; Ringquist R; Smith C; Ochoa MA; Roy K Adv Sci (Weinh); 2024 Dec; 11(45):e2402792. PubMed ID: 39352717 [TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a SARS-CoV-2 recombinant protein subunit vaccine adjuvanted with Alum + CpG 1018 in healthy Indonesian adults: A multicenter, randomized, comparative, observer-blind, placebo-controlled phase 2 study. Maddeppungeng M; Nurdin A; Nency YM; Sekartini R; Medise BE; Soedjatmiko S; Massi MN; Darma S; Darussalam AHE; Ramadhani N; Hidayah N; Chalid MT; Ramadany S; Wahyuni S; Djaharuddin I; Santoso A; Fikri B; Alimuddin S; Pelupessy NM; Masadah R; Putri AZ; Setyaningsih L; Yani FF; Anggrainy F; Deza PA; Maharani N; Mahati E; Hapsari R; Farhanah N; Pramudo SG; Tri Anantyo D Hum Vaccin Immunother; 2024 Dec; 20(1):2429231. PubMed ID: 39632708 [TBL] [Abstract][Full Text] [Related]
13. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. Liu X; Munro APS; Wright A; Feng S; Janani L; Aley PK; Babbage G; Baker J; Baxter D; Bawa T; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Fox L; Qureshi E; Goodman AL; Green CA; Haughney J; Hicks A; Jones CE; Kanji N; van der Klaauw AA; Libri V; Llewelyn MJ; Mansfield R; Maallah M; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Belhadef HT; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Saralaya D; Sharma S; Sheridan R; Stokes M; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN; J Infect; 2023 Jul; 87(1):18-26. PubMed ID: 37085049 [TBL] [Abstract][Full Text] [Related]
14. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Tang J; Zeng C; Cox TM; Li C; Son YM; Cheon IS; Wu Y; Behl S; Taylor JJ; Chakaraborty R; Johnson AJ; Shiavo DN; Utz JP; Reisenauer JS; Midthun DE; Mullon JJ; Edell ES; Alameh MG; Borish L; Teague WG; Kaplan MH; Weissman D; Kern R; Hu H; Vassallo R; Liu SL; Sun J Sci Immunol; 2022 Oct; 7(76):eadd4853. PubMed ID: 35857583 [TBL] [Abstract][Full Text] [Related]
15. Obtaining HBV core protein VLPs carrying SARS-CoV-2 nucleocapsid conserved fragments as vaccine candidates. Lobaina Y; Musacchio A; Ai P; Chen R; Suzarte E; Chinea G; Zhang M; Zhou Z; Lan Y; Silva R; Guillén G; Yang K; Li W; Perera Y; Hermida L Virol J; 2024 Nov; 21(1):310. PubMed ID: 39609857 [TBL] [Abstract][Full Text] [Related]
16. Exploring yeast glucans for vaccine enhancement: Sustainable strategies for overcoming adjuvant challenges in a SARS-CoV-2 model. Azevedo-Silva J; Amorim M; Tavares-Valente D; Sousa P; Mohamath R; Voigt EA; Guderian JA; Kinsey R; Viana S; Reis F; Pintado ME; Paddon CJ; Fox CB; Fernandes JC Eur J Pharm Biopharm; 2024 Dec; 205():114538. PubMed ID: 39461571 [TBL] [Abstract][Full Text] [Related]
17. Hybrid response to SARS-CoV-2 and Portilho AI; Hermes Monteiro da Costa H; Grando Guereschi M; Prudencio CR; De Gaspari E Hum Vaccin Immunother; 2024 Dec; 20(1):2346963. PubMed ID: 38745461 [TBL] [Abstract][Full Text] [Related]
18. Discovery of a Novel Public Antibody Lineage Correlated With Inactivated SARS-CoV-2 Vaccine and the Resultant Neutralization Activity. Wang J; Ni S; Chen Q; Wang C; Liu H; Huang L; Nasir MW; Wang W; Zhang X; Wu J; Liu Z; Wu J; Zhang L; Gao Y J Med Virol; 2024 Dec; 96(12):e70073. PubMed ID: 39610345 [TBL] [Abstract][Full Text] [Related]